TY - JOUR
T1 - Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S
AU - Harryvan, Tom J.
AU - Visser, Marten
AU - De Bruin, Linda
AU - Plug, Léonie
AU - Griffioen, Lisa
AU - Mulder, Arend
AU - Van Veelen, Peter A.
AU - Van Der Heden Van Noort, Gerbrand J.
AU - Jongsma, Marlieke L.M.
AU - Meeuwsen, Miranda H.
AU - Wiertz, Emmanuel J.H.J.
AU - Santegoets, Saskia J.
AU - Hardwick, James C.H.
AU - Van Hall, Thorbald
AU - Neefjes, Jacques
AU - Van Der Burg, Sjoerd H.
AU - Hawinkels, Lukas J.A.C.
AU - Verdegaal, Els M.E.
N1 - Funding Information:
Funding TH is sponsored by a personal PhD grant from the Leiden University Medical Center. EV is sponsored by a grant from the Dutch Cancer Society-KWF grant 2017-10815. GvdHvN is supported by NWO (VIDI grant 192.011). This work was supported by the Dutch Research Council (NWO) Medium Investment Grant 91116004 (partly financed by ZonMw) to PAVV. Competing interests None declared. Patient consent for publication Not applicable.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022.
PY - 2022/3/9
Y1 - 2022/3/9
N2 - Background Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present exogenous antigen, which molecular pathways are involved in this process and how this ultimately affects tumor-specific CD8+ T cell function is unknown. Methods In this study, we investigated the ability of human colorectal cancer (CRC)-derived CAFs to cross-present neoantigen-derived synthetic long peptides (SLPs), corresponding to tumor-derived mutant peptides, and how this affects tumor-specific T-cell function. Processing of the SLP was studied by targeting components of the cross-presentation machinery through CRISPR/Cas9 and siRNA-mediated genetic ablation to identify the key molecules involved in fibroblast-mediated cross-presentation. Multispectral flow cytometry and killing assays were performed to study the effect of fibroblast cross-presentation on T cell function. Results Here, we show that human CRC-derived CAFs display an enhanced capacity to cross-present neoantigen-derived SLPs when compared with normal colonic fibroblasts. Cross-presentation of antigens by fibroblasts involved the lysosomal protease cathepsin S. Cathepsin S expression by CAFs was detected in situ in human CRC tissue, was upregulated in ex vivo cultured CRC-derived CAFs and showed increased expression in normal fibroblasts after exposure to CRC-conditioned medium. Cognate interaction between CD8+ T cells and cross-presenting CAFs suppressed T cell function, reflected by decreased cytotoxicity, reduced activation (CD137) and increased exhaustion (TIM3, LAG3 and CD39) marker expression. Conclusion These data indicate that CAFs may directly suppress tumor-specific T cell function in an antigen-dependent fashion in human CRC.
AB - Background Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present exogenous antigen, which molecular pathways are involved in this process and how this ultimately affects tumor-specific CD8+ T cell function is unknown. Methods In this study, we investigated the ability of human colorectal cancer (CRC)-derived CAFs to cross-present neoantigen-derived synthetic long peptides (SLPs), corresponding to tumor-derived mutant peptides, and how this affects tumor-specific T-cell function. Processing of the SLP was studied by targeting components of the cross-presentation machinery through CRISPR/Cas9 and siRNA-mediated genetic ablation to identify the key molecules involved in fibroblast-mediated cross-presentation. Multispectral flow cytometry and killing assays were performed to study the effect of fibroblast cross-presentation on T cell function. Results Here, we show that human CRC-derived CAFs display an enhanced capacity to cross-present neoantigen-derived SLPs when compared with normal colonic fibroblasts. Cross-presentation of antigens by fibroblasts involved the lysosomal protease cathepsin S. Cathepsin S expression by CAFs was detected in situ in human CRC tissue, was upregulated in ex vivo cultured CRC-derived CAFs and showed increased expression in normal fibroblasts after exposure to CRC-conditioned medium. Cognate interaction between CD8+ T cells and cross-presenting CAFs suppressed T cell function, reflected by decreased cytotoxicity, reduced activation (CD137) and increased exhaustion (TIM3, LAG3 and CD39) marker expression. Conclusion These data indicate that CAFs may directly suppress tumor-specific T cell function in an antigen-dependent fashion in human CRC.
KW - antigen presentation
KW - gastrointestinal neoplasms
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85126169622&partnerID=8YFLogxK
U2 - 10.1136/jitc-2021-003591
DO - 10.1136/jitc-2021-003591
M3 - Article
C2 - 35264435
AN - SCOPUS:85126169622
VL - 10
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 3
M1 - e003591
ER -